Memory T cells specific for novel human papillomavirus type 16 (HPV16) E6 epitopes in women whose HPV16 infection has become undetectable

Clinical and Vaccine Immunology

Volumn 15, Issue 6, 2008, Pages 937-945

  Wang, Xuelian ^a,b   Moscicki, Anna Barbara ^c   Tsang, Laura ^a   Brockman, Andrea ^a   Nakagawa, Mayumi ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CHINA MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEUKOCYTE ANTIGEN; PROTEIN E6;

AMINO ACID SEQUENCE; ARTICLE; BLOOD SAMPLING; CASE REPORT; CD8+ T LYMPHOCYTE; CELL CLONE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; EPITOPE MAPPING; FEMALE; HIGH RISK PATIENT; HLA SYSTEM; HLA TYPING; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; MEMORY T LYMPHOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VERRUCA VULGARIS;

CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; EPITOPES, T-LYMPHOCYTE; FEMALE; HLA-A ANTIGENS; HLA-B ANTIGENS; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOLOGIC MEMORY; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; REPRESSOR PROTEINS;

EID: 47049088178     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00404-07     Document Type: Article

References (33)

1. Alexander, M., M. L. Salgaller, E. Celis, A. Sette, W. A. Barnes, S. A. Rosenberg, and M. A. Steller. 1996. Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope. Am. J. Obstet. Gynecol. 175:1586-1593.
2. Bontkes, H. J., T. D. de Gruijl, J. M. Walboomers, A. J. van den Muysenberg, A. W. Gunther, R. J. Scheper, C. J. Meijer, and J. A. Kummer. 1997. Assessment of cytotoxic T-lymphocyte phenotype using the specific markers granzyme B and TIA-1 in cervical neoplastic lesions. Br. J. Cancer 76:1353-1360.
3. Bourgault Villada, I., N. Beneton, C. Bony, F. Connan, J. Monsonego, A. Bianchi, P. Saiag, J. P. Levy, J. G. Guillet, and J. Choppin. 2000. Identification in humans of HPV-16 E6 and E7 protein epitopes recognized by cytolytic T lymphocytes in association with HLA-B18 and determination of the HLA-B18-specific binding motif. Eur. J. Immunol. 30:2281-2289.
4. Crook, T., J. A. Tidy, and K. H. Vousden. 1991. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 67:547-556.
5. Demkowicz, W. E., Jr., R. A. Littaua, J. Wang, and F. A. Ennis. 1996. Human cytotoxic T-cell memory: long-lived responses to vaccinia virus. J. Virol. 70:2627-2631.
6. Evans, E. M., S. Man, A. S. Evans, and L. K. Borysiewicz. 1997. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res. 57:2943-2950.
7. Feltkamp, M. C., H. L. Smits, M. P. Vierboom, R. P. Minnaar, B. M. de Jongh, J. W. Drijfhout, J. ter Schegget, C. J. Melief, and W. M. Kast. 1993. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23:2242-2249.
8. + T cells from healthy young women. J. Gen. Virol. 88:1470-1478.
9. Garcia, F., K. U. Petry, L. Muderspach, M. A. Gold, P. Braly, C. P. Crum, M. Magill, M. Silverman, R. G. Urban, M. L. Hedley, and K. J. Beach. 2004. ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet. Gynecol. 103:317-326.
10. + T cells after clearance of hepatitis C virus. J. Immunol. 169:2210-2214.
11. + T-cell epitopes. J. Virol. 80:4717-4728.
12. Greenberg, P. D. 1991. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49:281-355.
13. Hoffmann, T. K., C. Arsov, K. Schirlau, M. Bas, U. Friebe-Hoffmann, J. P. Klussmann, K. Scheckenbach, V. Balz, H. Bier, and T. L. Whiteside. 2006. T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx. Int. J. Cancer 118:1984-1991.
14. Kaech, S. M., E. J. Wherry, and R. Ahmed. 2002. Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. 2:251-262.
15. Keating, S. M., P. Bejon, T. Berthoud, J. M. Vuola, S. Todryk, D. P. Webster, S. J. Dunachie, V. S. Moorthy, S. J. McConkey, S. C. Gilbert, and A. V. Hill. 2005. Durable human memory T cells quantifiable by cultured enzymelinked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J. Immunol. 175:5675-5680.
16. Kim, K. H., R. Dishongh, A. D. Santin, M. J. Cannon, S. Bellone, and M. Nakagawa. 2006. Recognition of a cervical cancer derived tumor cell line by a human papillomavirus type 16 E6 52-61-specific CD8 T cell clone. Cancer Immun. 6:9.
17. Marsh, S. G. E., P. Parham, and L. D. Barber. 2000. The HLA FactsBook. Academic Press, San Diego, CA.
18. Moscicki, A. B., S. Shiboski, J. Broering, K. Powell, L. Clayton, N. Jay, T. M. Darragh, R. Brescia, S. Kanowitz, S. B. Miller, J. Stone, E. Hanson, and J. Palefsky. 1998. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J. Pediatr. 132:277-284.
19. Muderspach, L., S. Wilczynski, L. Roman, L. Bade, J. Felix, L. A. Small, W. M. Kast, G. Fascio, V. Marty, and J. Weber. 2000. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin. Cancer Res. 6:3406-3416.
20. Nakagawa, M., K. H. Kim, and A.-B. Moscicki. 2004. Different methods of identifying new antigenic epitopes of human papillomavirus type 16 E6 and E7 proteins. Clin. Diagn. Lab. Immunol. 11:889-896.
21. Nakagawa, M., K. H. Kim, T. M. Gillam, and A.-B. Moscicki. 2007. HLA class I binding promiscuity of the CD8 T-cell epitopes of human papillomavirus type 16 E6 protein. J. Virol. 81:1412-1423.
22. Nakagawa, M., K. H. Kim, and A. B. Moscicki. 2005. Patterns of CD8 T-cell epitopes within the human papillomavirus type 16 (HPV 16) E6 protein among young women whose HPV 16 infection has become undetectable. Clin. Diagn. Lab. Immunol. 12:1003-1005.
23. Nakagawa, M., D. P. Stites, S. Farhat, J. R. Sisler, B. Moss, F. Kong, A. B. Moscicki, and J. M. Palefsky. 1997. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. J. Infect. Dis. 175:927-931.
24. Nakagawa, M., D. P. Stites, S. Patel, S. Farhat, M. Scott, N. K. Hills, J. M. Palefsky, and A. B. Moscicki. 2000. Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. J. Infect. Dis. 182:595-598.
25. Ressing, M. E., A. Sette, R. M. Brandt, J. Ruppert, P. A. Wentworth, M. Hartman, C. Oseroff, H. M. Grey, C. J. Melief, and W. M. Kast. 1995. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A* 0201-binding peptides. J. Immunol. 154:5934-5943.
26. Ressing, M. E., W. J. van Driel, R. M. Brandt, G. G. Kenter, J. H. de Jong, T. Bauknecht, G. J. Fleuren, P. Hoogerhout, R. Offringa, A. Sette, E. Celis, H. Grey, B. J. Trimbos, W. M. Kast, and C. J. Melief. 2000. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J. Immunother. 23:255-266.
27. Ting, Y., and M. M. Manos. 1990. Detection and typing of genital human papillomaviruses. Academic Press, San Diego, CA.
28. Vousden, K. 1993. Interactions of human papillomavirus transforming proteins with the products of tumor suppressor genes. FASEB J. 7:872-879.
29. Walboomers, J. M., M. V. Jacobs, M. M. Manos, F. X. Bosch, J. A. Kummer, K. V. Shah, P. J. Snijders, J. Peto, C. J. Meijer, and N. Munoz. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:12-19.
30. Youde, S. J., P. R. Dunbar, E. M. Evans, A. N. Fiander, L. K. Borysiewicz, V. Cerundolo, and S. Man. 2000. Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens. Cancer Res. 60:365-371.
31. Zehbe, I., A. M. Kaufmann, M. Schmidt, H. Hohn, and M. J. Maeurer. 2007. Human papillomavirus 16 E6-specific CD45RA+ CCR7+ high avidity CD8+ T cells fail to control tumor growth despite interferon-gamma production in patients with cervical cancer. J. Immunother. 30:523-532.
32. zur Hausen, H. 1999. Immortalization of human cells and their malignant conversion by high risk human papillomavirus genotypes. Semin. Cancer Biol. 9:405-411.
33. zur Hausen, H. 1996. Papillomavirus infections - a major cause of human cancers. Biochim. Biophys. Acta 1288:F55-F78.